Back to search

Article

Downregulated Interferon Signalling in T Cells is Associated with Response to Vedolizumab in Inflammatory Bowel Disease

2026-05-13

Abstract excerpt

<h4>Background</h4> Vedolizumab, a gut-selective anti-integrin therapy, is effective in IBD, but response rates remain variable. Conventional clinical and biochemical markers, including C-reactive protein and faecal calprotectin, have limited predictive value. Although recent transcriptomic studies have implicated T-cell–related signatures in predicting vedolizumab response, these findings lack validation across...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
1f8f5799-7d02-5cad-bc3f-0edb6c111c3a
DOI
10.64898/2026.05.11.26352882
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Downregulated Interferon Signalling in T Cells is Associated with Response to Vedolizumab in Inflammatory Bowel DiseaseDOI 10.64898/2026.05.11.26352882
High-dimensional single-cell analysis identifies cellular signatures associated with response to vedolizumab therapy in ulcerative colitisSemantic proximity
Multimodal Profiling of Peripheral Blood Identifies Proliferating Circulating Effector CD4+ T Cells as Predictors for Response to Integrin α4β7-Blocking Therapy in Inflammatory Bowel Disease.Semantic proximity
Single-cell and spatial multi-omics highlight effects of anti-integrin therapy across cellular compartments in ulcerative colitisSemantic proximity
Single-cell characterization of peripheral blood mononuclear cells from vedolizumab-treated patients with Crohn's disease identifies response-associated differences among the plasmacytoid dendritic cell and classical monocyte populations.Semantic proximity
Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.Semantic proximity
Gene Expression Profiling and Response Signatures Associated With Differential Responses to Infliximab Treatment in Ulcerative ColitisSemantic proximity
Limited predictive value of the gut microbiome and metabolome for response to biological therapy in inflammatory bowel diseaseSemantic proximity
Baseline expression of immune gene modules in blood is associated with primary response to anti-TNF therapy in Crohn’s disease patientsSemantic proximity
The Clinical Response of Upadacitinib and Risankizumab is Associated with Reduced Inflammatory Bowel Disease Anti-TNFα Inadequate Response MechanismsSemantic proximity
A longitudinal single-cell therapeutic atlas of anti-tumour necrosis factor treatment in inflammatory bowel diseaseSemantic proximity
Molecular characterization of response to etrolizumab and anti-TNF reveals treatment resistance in ulcerative colitis is associated with an abundance of residual neutrophil subsets and inflammatory fibroblast populationsSemantic proximity
Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.Semantic proximity
Select a neighboring publication to make it the new centre.